header image

Vienna, Austria

History:

 

The Vienna facility was the first Octapharma-owned production site. The premises were acquired in 1989 from the state-owned Heilmittelwerke Austria/Chemie Linz, the first to manufacture a solvent-detergent (S/D) treated FVIII preparation and later the first     virus-inactivated plasma for transfusion. The size of the premises has nearly doubled to 54,000m², the original buildings have been upgraded, equipment has been installed with the latest in production and laboratory technology and new buildings have been constructed. The facility's annual fractionation capacity has grown seven-fold since 1989. In the beginning, there were 80 staff, the facility now employs around 740 people. Recent projects include the implementation of a state-of-the-art isolator filling line for small volume parenterals as well as the implementation of an additional robot loaded freeze dryer.

 

One of the new buildings houses a new filling line for large volume parenterals and a freeze drying unit with an automatic loading and unloading robot—all using state-of-the-art isolator technology—as well as a protein purification unit providing dedicated production lines for each product. A new utility complex provides the production media for the entire facility. Together, these investments make the Vienna site one of the most modern fractionation facilities in the world.

 

In order to meet the challenges of safe and economical fractionation, tremendous efforts have gone into implementing and continuously upgrading the site's Quality Systems. The facility itself and its Quality Systems are subject to regular audits by authorities from all over the world. In 2004, the facility was licensed with the FDA and currently manufactures three products for the US market, with additional licenses pending.

 

On-site units:

 

Fractionation/purification; pharmaceutical production; labeling, packaging and storage facilities; Quality Control; Research & Development (R&D) laboratories; administrative units; clinical R&D unit.

 

On-site subsidiaries:

 

Octapharma Pharmazeutika Produktionsges m.b.H. (Operations)

Octapharma Handelsgesellschaft m.b.H. (Marketing & Sales)